SM
ANIP icon

Sabby Management’s ANI Pharmaceuticals ANIP Stock Holding History

Sabby Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,219
Closed -$24K – 237
2013
Q4 		$24K Buy
+1,219
New +$15.8K ﹤0.01% 213

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sabby Management's ANIP Position: Q1 2014 in Review

Sabby Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2014, closing a stake of 1,219 shares — an estimated $24K sold.

Sabby Management first reported a position in ANIP in Q4 2013 and held it in 1 quarter. The position peaked at $24K in Q4 2013. 67 funds tracked by Wall St. Rank hold ANIP as of Q1 2014.

  • Sabby Management reported no remaining ANI Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Sabby Management sold 1,219 ANI Pharmaceuticals shares in Q1 2014, an estimated $24K.
  • Sabby Management first reported a position in ANI Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Sabby Management's ANI Pharmaceuticals position peaked at $24K in Q4 2013.
  • 67 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2014.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.